vimarsana.com

Latest Breaking News On - Raju prasad - Page 1 : vimarsana.com

CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 5 9%

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s share price traded up 5.9% during mid-day trading on Wednesday . The company traded as high as $66.13 and last traded at $66.00. 856,731 shares were traded during trading, a decline of 48% from the average session volume of 1,654,993 shares. The stock had previously closed at […]

CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 5 9%

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s share price traded up 5.9% during mid-day trading on Wednesday . The company traded as high as $66.13 and last traded at $66.00. 856,731 shares were traded during trading, a decline of 48% from the average session volume of 1,654,993 shares. The stock had previously closed at […]

CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $84 00

CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Citigroup from $89.00 to $84.00 in a report issued on Thursday morning, Benzinga reports. Citigroup currently has a buy rating on the stock. Several other research firms have also recently weighed in on CRSP. TheStreet upgraded shares of CRISPR Therapeutics from a d+ […]

CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0 2% on Analyst Downgrade

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) shares dropped 0.2% during mid-day trading on Friday after Citigroup lowered their price target on the stock from $89.00 to $84.00. Citigroup currently has a buy rating on the stock. CRISPR Therapeutics traded as low as $55.21 and last traded at $55.61. Approximately 176,023 shares traded hands […]

CRISPR Therapeutics (NASDAQ:CRSP) PT Lowered to $84 00 at Citigroup

CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price objective lowered by Citigroup from $89.00 to $84.00 in a research report report published on Thursday, Benzinga reports. Citigroup currently has a buy rating on the stock. Several other analysts have also recently commented on CRSP. Robert W. Baird increased their target price on CRISPR Therapeutics […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.